Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · Real-Time Price · USD
220.36
-0.14 (-0.06%)
At close: Dec 5, 2025, 4:00 PM EST
219.64
-0.72 (-0.33%)
After-hours: Dec 5, 2025, 7:16 PM EST
Cidara Therapeutics Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for Cidara Therapeutics stock ranges from a low of $35 to a high of $200. The average analyst price target of $128.75 forecasts a -41.57% decrease in the stock price over the next year.
Price Target: $128.75 (-41.57%)
Analyst Consensus: Buy
* Price targets were last updated on Nov 7, 2025.
Analyst Ratings
The average analyst rating for Cidara Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 4 | 3 |
| Buy | 5 | 5 | 4 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 11 | 13 | 13 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 18, 2025 |
| Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 14, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $137 → $145 | Buy | Maintains | $137 → $145 | -34.20% | Nov 7, 2025 |
| Needham | Needham | Strong Buy Maintains $100 → $135 | Strong Buy | Maintains | $100 → $135 | -38.74% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
n/a
from 1.28M
Revenue Next Year
8.60M
EPS This Year
-8.30
from -26.75
EPS Next Year
-6.40
from -8.30
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 31.5M | ||||
| Avg | n/a | 8.6M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -6.26 | -4.25 | ||||
| Avg | -8.30 | -6.40 | ||||
| Low | -8.98 | -9.86 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.